Apixaban is an oral, direct factor Xa inhibitor that inhibits both free and clot-bound factor Xa,
and has been approved for clinical use in several thromboembolic disorders, including …

Abstract The American Society of Regional Anesthesia and Pain Medicine (ASRA) 2012
survey of meeting attendees showed that existing ASRA anticoagulation guidelines for …

The most commonly prescribed oral anticoagulants worldwide are the vitamin K antagonists
(VKAs) such as warfarin. Factors affecting the pharmacokinetics of VKAs are important …

Millions of individuals in the United States require long-term treatment with an oral
anticoagulant. For decades, vitamin K antagonists were the only oral option available; …

An open‐label, parallel‐group, single‐dose study was conducted to assess the
pharmacokinetics, pharmacodynamics, and safety of apixaban in 8 subjects with end‐stage …

Interventional spine and pain procedures cover a far broader spectrum than those for
regional anesthesia, reflecting diverse targets and goals. When surveyed, interventional …

In 2012, the Japan Gastroenterological Endoscopy Society published “Guidelines for
Gastroenterological Endoscopy in Patients Undergoing Antithrombotic Treatment” …

Aim Apixaban is an oral factor X a inhibitor approved for stroke prevention in atrial fibrillation
and thromboprophylaxis in patients who have undergone elective hip or knee replacement …

Aim Apixaban is an oral, direct, factor‐X a inhibitor approved for thromboprophylaxis in
patients who have undergone elective hip or knee replacement surgery and for prevention …

The introduction of direct oral anticoagulants (DOACs), such as dabigatran, rivaroxaban,
apixaban, edoxaban, and betrixaban, provides safe and effective alternative to previous …